This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Clover Biopharmaceuticals Gelecekteki Büyüme

We currently don't have sufficient analyst coverage to forecast growth and revenue for Clover Biopharmaceuticals.

n/a

Kazanç büyüme oranı

190.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	39.9%
Gelir büyüme oranı	47.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	27 Jul 2023

Güncelleme yok

Kazanç ve Gelir Büyüme Tahminleri

SHSC:2197 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	2,341	N/A	N/A	N/A	1
12/31/2024	3,071	N/A	N/A	N/A	2
12/31/2023	2,571	N/A	N/A	N/A	2
6/30/2023	0	-665	N/A	N/A	N/A
3/31/2023	0	-1,559	N/A	N/A	N/A
12/31/2022	N/A	-2,452	-1,796	-1,691	N/A
9/30/2022	N/A	-4,145	-1,461	-1,356	N/A
6/30/2022	N/A	-5,838	-1,125	-1,021	N/A
3/31/2022	N/A	-5,927	-1,062	-969	N/A
12/31/2021	N/A	-6,016	-998	-918	N/A
12/31/2020	N/A	-913	363	477	N/A

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if 2197's forecast earnings growth is above the savings rate (1.9%).

Kazançlar ve Piyasa: Insufficient data to determine if 2197's earnings are forecast to grow faster than the Hong Kong market

Yüksek Büyüme Kazançları: Insufficient data to determine if 2197's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: 2197's revenue (47.9% per year) is forecast to grow faster than the Hong Kong market (8.7% per year).

Yüksek Büyüme Geliri: 2197's revenue (47.9% per year) is forecast to grow faster than 20% per year.

Gelecekteki ROE: Insufficient data to determine if 2197's Return on Equity is forecast to be high in 3 years time